Max Healthcare Shares Under Pressure? JM Financial Assigns ‘REDUCE’ Rating; Check Target Price and Key Reason

Max Healthcare Institute has reported growth in revenue and profitability for the first quarter of financial year 2027 (Q1FY27). However, brokerage firm JM Financial has adopted a cautious stance on the stock, citing concerns over growth momentum.

The brokerage has assigned a ‘REDUCE’ rating to Max Healthcare, with the company's performance reportedly falling short of expectations in some key areas.

Max Healthcare Q1FY27 Results: Revenue and EBITDA Rise 15%

According to JM Financial's report, Max Healthcare's revenue and EBITDA increased 15% year-on-year in Q1FY27.

The company's EBITDA margin remained broadly stable at 24.6%.

The hospital business benefited from improved operating metrics, with bed occupancy increasing 10% and ARPOB (Average Revenue Per Occupied Bed) rising 5%.

Despite these positive numbers, JM Financial believes the overall growth trajectory remains below expectations.

Why Did JM Financial Give a ‘REDUCE’ Rating?

The brokerage has highlighted two major concerns that could weigh on Max Healthcare's future growth.

1. Oncology Drug Prices Impact Revenue Mix

One of the key concerns relates to the oncology business.

According to the report, the discontinuation of certain chemotherapy drugs has affected the company's oncology revenue contribution. The share of oncology in inpatient revenue has declined from 26% to 22%.

Since oncology is an important component of hospital revenue, the change in the revenue mix could affect growth expectations going forward.

2. Delay in Adding New Beds

The second major concern is the slower pace of capacity expansion.

Max Healthcare has been adding new beds as part of its expansion strategy, but the pace of new-bed additions has reportedly been slower than expected.

A delay in expanding capacity could limit the company's ability to sustain higher revenue growth over the longer term.

Max Healthcare Stock: What Investors Should Watch

The Q1FY27 results show that Max Healthcare continues to deliver growth, particularly through improved occupancy and higher revenue per occupied bed.

However, investors will need to monitor:

The recovery of oncology-related revenue.

The pace of new-bed additions.

Occupancy levels across the hospital network.

ARPOB growth.

EBITDA margins and profitability.

The company's ability to meet future expansion targets.

Max Healthcare Share News: Key Takeaway

While Max Healthcare delivered 15% YoY growth in both revenue and EBITDA in Q1FY27, JM Financial remains cautious because growth has not fully met expectations.

The declining contribution from oncology revenue and delays in capacity expansion are the two key concerns highlighted by the brokerage. Investors should therefore consider these factors alongside the company's financial performance before making any investment decision.